MedTrace Logo

Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches

NCT00172094 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 189

Last updated 2021-06-03

No results posted yet for this study

Summary

The purpose of this study was to evaluate the effectiveness and safety of a single oral dose of NPS 1776 in the acute treatment of migraine pain and associated symptoms.

Conditions

  • Migraine Headache

Interventions

DRUG

NPS 1776 (800 mg)

NPS 1776 (800 mg) powder

DRUG

PLACEBO

Placebo in non-carbonated fruit flavored drink (150 ml)

DRUG

NPS 1776 (400 mg)

NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2004-06-30
Completion
2004-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00172094 on ClinicalTrials.gov